Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2′-deoxyuridine

[1]  F. Demard,et al.  Influence of sex and age on fluorouracil clearance. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T R Fleming,et al.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. , 1990, The New England journal of medicine.

[3]  B. Levin,et al.  Treatment of advanced colorectal cancer. , 1989, Hematology/oncology clinics of North America.

[4]  H. Pinedo,et al.  Fluorouracil: biochemistry and pharmacology. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Keizer,et al.  Bioanalysis of fluorouracil applying liquid chromatography and valve switching , 1988 .

[6]  E. Clercq,et al.  Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil against adenocarcinoma 755 in mice. Increased therapeutic index and correlation with increased plasma 5-fluorouracil levels. , 1988 .

[7]  E. De Clercq,et al.  Combined effects of bromovinyldeoxyuridine and fractionated or continuous administration of 5-fluorouracil in P388 leukemia-bearing mice. , 1988, Cancer letters.

[8]  E. De Clercq,et al.  The antitumor potency of oral tegafur against adenocarcinoma 755 in mice is markedly enhanced by oral (E)-5-(2-bromovinyl)-2'-deoxyuridine. , 1987, Japanese journal of cancer research : Gann.

[9]  C. V. D. van de Velde,et al.  Non-linear pharmacokinetics of 5-fluorouracil as described by in vivo behaviour of 5,6 dihydro-5-fluorouracil. , 1986, Biochemical pharmacology.

[10]  E. De Clercq,et al.  Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice. , 1986, Cancer research.

[11]  J. Jacobs,et al.  A randomized trial of cisplatin (CACP) + 5‐fluorouracil (5‐FU) infusion and CACP + 5‐FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck , 1985, Cancer.

[12]  L. Yang,et al.  Cellular basis for the inefficacy of 5-FU in human colon carcinoma. , 1985, Cancer treatment reports.

[13]  T. Fleming,et al.  A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Tuchman,et al.  Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase. , 1985, Cancer research.

[15]  N. Vogelzang.  Continuous infusion chemotherapy: a critical review. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  E. De Clercq,et al.  Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine treatment of severe herpes zoster in cancer patients. , 1984, European journal of cancer & clinical oncology.

[17]  Y. Rustum,et al.  Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. , 1982, Cancer research.

[18]  N. Kemeny,et al.  Combination clinical trials with thymidine and fluorouracil: A phase I and clinical pharmacologic evaluation , 1980, Cancer.

[19]  S. Spiegelman,et al.  An overview of thymidine , 1980, Cancer.

[20]  R. T. Walker,et al.  (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[21]  E. North.  Remarks on Somnambulism, Etc , 1835 .

[22]  E. De Clercq,et al.  Effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on life-span and 5-fluorouracil metabolism in mice with hepatic metastases. , 1990, European journal of cancer.

[23]  Emmanuel Mitry,et al.  Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. , 1990, The New England journal of medicine.

[24]  R. Diasio,et al.  Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. , 1988, The Journal of clinical investigation.

[25]  E. De Clercq,et al.  Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil against adenocarcinoma 755 in mice. Increased therapeutic index and correlation with increased plasma 5-fluorouracil levels. , 1988, Biochemical pharmacology.

[26]  H. Keizer,et al.  Bioanalysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine. , 1988, Journal of chromatography.

[27]  E. Declercq.  Potential of bromovinyldeoxyuridine in anticancer chemotherapy. , 1986 .

[28]  E. De Clercq.  Potential of bromovinyldeoxyuridine in anticancer chemotherapy. , 1986, Anticancer research.

[29]  E. De Clercq,et al.  Effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on several parameters of Epstein-Barr virus infection. , 1984, The Journal of general virology.

[30]  J. Kirkwood,et al.  Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial. , 1980, Cancer research.

[31]  C. Presant,et al.  Phase I study of thymidine plus 5-fluorouracil infusions in advanced colorectal carcinoma. , 1979, Cancer treatment reports.